Drugs / ABO2011
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06088004 | Sep 2023 → Dec 2026 expected | cancer | Suzhou Abogen Biosciences Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABO2011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06088004 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA encoding human single-chain IL-12 protein” NCT06088004 ↗ |
| Route | Other | “intratumoral injection” NCT06088004 ↗ |